Spero Therapeutics, Inc.
SPRO
Health Care
2
exclusion reasons
1 theme
Spero Therapeutics, Inc. is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose drug development pipeline requires animal testing for regulatory compliance. The company's public filings, including its 2025 Form 10-K, explicitly state that its research activities are subject to the U.S. Department of Agriculture's Animal Welfare Act and Good Laboratory Practice (GLP) regulations. Cruelty Free Investors lists Spero Therapeutics among companies that exploit animals for testing. The company's published research, such as a 2022 study on antibacterial efficacy co-authored by its employees, relies on data from animal models. As a pharmaceutical developer, animal testing is a central and unavoidable component of Spero's business model for bringing new drug candidates to market.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose core business of developing novel antibacterial treatments necessitates animal testing as part of the drug development process. The company's pipeline candidates, including SPR994 (tebipenem HBr) and SPR720, have progressed through preclinical stages involving animal studies to evaluate efficacy and safety, a standard requirement for regulatory approval of new chemical entities.
Specific research documents detail this reliance on animal models. For instance, a 2024 study on SPR720 published in a scientific journal explicitly notes its "efficacy... in murine models," indicating the use of mice in its development program. Similarly, company filings reference the completion of "preclinical laboratory tests [and] animal studies" as part of its development workflow. As a pharmaceutical company seeking FDA approval for its products, Spero Therapeutics conducts, funds, and relies upon animal testing to advance its clinical assets toward commercialization.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.